Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 23;24(20):15472.
doi: 10.3390/ijms242015472.

Neurohumoral Activation in Heart Failure

Affiliations
Review

Neurohumoral Activation in Heart Failure

Antonis A Manolis et al. Int J Mol Sci. .

Abstract

In patients with heart failure (HF), the neuroendocrine systems of the sympathetic nervous system (SNS), the renin-angiotensin-aldosterone system (RAAS) and the arginine vasopressin (AVP) system, are activated to various degrees producing often-observed tachycardia and concomitant increased systemic vascular resistance. Furthermore, sustained neurohormonal activation plays a key role in the progression of HF and may be responsible for the pathogenetic mechanisms leading to the perpetuation of the pathophysiology and worsening of the HF signs and symptoms. There are biomarkers of activation of these neurohormonal pathways, such as the natriuretic peptides, catecholamine levels and neprilysin and various newer ones, which may be employed to better understand the mechanisms of HF drugs and also aid in defining the subgroups of patients who might benefit from specific therapies, irrespective of the degree of left ventricular dysfunction. These therapies are directed against these neurohumoral systems (neurohumoral antagonists) and classically comprise beta blockers, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers and vaptans. Recently, the RAAS blockade has been refined by the introduction of the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan, which combines the RAAS inhibition and neprilysin blocking, enhancing the actions of natriuretic peptides. All these issues relating to the neurohumoral activation in HF are herein reviewed, and the underlying mechanisms are pictorially illustrated.

Keywords: angiotensin receptor blocker; angiotensin-converting enzyme inhibitor; beta blocker; neprilysin inhibitors; neurohormonal activity; neurohumoral activation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
This is the schema of the intricate relationship between the various aspects and biological systems of neurohumoral activation and components of the heart failure (HF) syndrome (see text for discussion). AVP = arginine vasopressin; BNP = brain natriuretic peptide; BP = blood pressure; HF = heart failure; RAAS = renin–angiotensin–aldosterone system; SNS = sympathetic nervous system.

References

    1. Grosman-Rimon L., Billia F., Wright E., Carasso S., Elbaz-Greener G., Kachel E., Rao V., Cherney D. Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. Heart Fail. Rev. 2020;25:685–701. doi: 10.1007/s10741-019-09860-8. - DOI - PubMed
    1. Ge Z., Li A., McNamara J., Dos Remedios C., Lal S. Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: Translation to human studies. Heart Fail. Rev. 2019;24:743–758. doi: 10.1007/s10741-019-09806-0. - DOI - PubMed
    1. Nägele M.P., Barthelmes J., Kreysing L., Haider T., Nebunu D., Ruschitzka F., Sudano I., Flammer A.J. Endocrine hormone imbalance in heart failure with reduced ejection fraction: A cross-sectional study. Health Sci. Rep. 2022;5:e880. doi: 10.1002/hsr2.880. - DOI - PMC - PubMed
    1. Lip G.Y., Heinzel F.R., Gaita F., Juanatey J.R., Le Heuzey J.Y., Potpara T., Svendsen J.H., Vos M.A., Anker S.D., Coats A.J., et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2016;18:12–36. doi: 10.1093/europace/euv191. - DOI - PubMed
    1. Manolis A.S., Varriale P., Nobile J. Short-term hemodynamic effects of intravenous methyldopa in patients with congestive heart failure. Pharmacotherapy. 1987;7:216–222. doi: 10.1002/j.1875-9114.1987.tb03528.x. - DOI - PubMed

MeSH terms